Oligonucleotide API Market Outlook:
Oligonucleotide API Market size was over USD 3.07 billion in 2025 and is anticipated to cross USD 7.75 billion by 2035, growing at more than 9.7% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of oligonucleotide API is estimated at USD 3.34 billion.
The growth of the market can be attributed to the rise in laboratory and research institute experiments worldwide. The Increasing use of oligonucleotides for various applications such as gene editing, diagnostics, therapeutics, and so on has driven the surge in interest in APIs across organizations. As per the data by the World Bank, as of 2018, there were 1597 researchers per 1,000,000 people involved in research and development activities across the globe, an increase from 1412 researchers per million in 2015. Further, the growing use of oligonucleotides in the effective treatment of several disorders is another major factor that is estimated to push the market growth further throughout the forecast period.
In addition to these, factors that are believed to fuel the market growth of oligonucleotide API include the worldwide rising proportion of oligonucleotide API in the drug pipeline which is estimated to accelerate the global oligonucleotide API market size in coming years. The oligonucleotide is a new type of therapeutic molecule ideal for treating a variety of diseases. Oligonucleotide base pairs with DNA or RNA to form a structure. In PCR (polymerase chain reaction), oligonucleotides are commonly used as primers. In addition, funding in life science activities, innovative product launches, and drug discovery, along with investments in high-profile big science projects are expected to drive demand for oligonucleotide API during the forecast period. For instance, according to estimates, governments around the world and international organizations are expected to invest a total of more than USD 170 billion on large-scale science projects between 2022 and 2025.
Key Oligonucleotide API Market Insights Summary:
Regional Highlights:
- North America in the oligonucleotide API market is anticipated to command a 36% revenue share by 2035, driven by increased healthcare spending, advanced healthcare infrastructure, and rising R&D investments in novel drug discovery and commercialization of oligonucleotide therapies.
- Europe is projected to witness lucrative growth by 2035, owing to escalating investments in research and development and the growing emphasis on precision medicine for cancer treatment.
Segment Insights:
- The pharmaceutical companies segment of the oligonucleotide API market is projected to account for the largest share by 2035, propelled by increasing adoption of innovative technologies to enhance drug efficacy and reduce development costs.
- The antisense oligonucleotides segment is anticipated to secure a significant share of the market by 2035, driven by the rising focus on personalized medicine and growing prevalence of Alzheimer’s disease.
Key Growth Trends:
- Globally Rising Prevalence of Cancer and Neurodegenerative Diseases
- Growth in Percentage of API Manufacturing Facilities
Major Challenges:
- High Production of Waste Associated with Oligonucleotide
- Complex Procedure of Manufacturing
Key Players: The General Motors Company, Autoliv Inc., Mitsubishi Heavy Industries, Ltd., Continental AG, Faurecia SE, Robert Bosch GmbH, Delphi Group, Panasonic Holdings Corporation, Tenneco Inc., Cummins Inc.
Global Oligonucleotide API Market Forecast and Regional Outlook:
Market Size & Growth Projections:
- 2025 Market Size: USD 3.07 billion
- 2026 Market Size: USD 3.34 billion
- Projected Market Size: USD 7.75 billion by 2035
- Growth Forecasts: 9.7% CAGR (2026-2035)
Key Regional Dynamics:
- Largest Region: North America (36% Share by 2035)
- Fastest Growing Region: Asia Pacific
- Dominating Countries: United States, Switzerland, Germany, Japan, United Kingdom
- Emerging Countries: China, India, Japan, South Korea, Singapore
Last updated on : 25 February, 2026
Oligonucleotide API Market - Growth Drivers and Challenges
Growth Drivers
- Globally Rising Prevalence of Cancer and Neurodegenerative Diseases - Based on data from the National Cancer Institute, as of 2020, there were 1,806,590 new cancer diagnoses in the United States and 606,520 cancer deaths. The rising number of cancer cases is propelling the demand for advanced testing procedures. Moreover, the treatment of neurodegenerative diseases requires a personalized approach as well. In terms of neurodegenerative conditions, Alzheimer's disease is one of the most common. There are several limitations associated with conventional medicine in this area, so oligonucleotide APIs are being studied extensively. This factor is expected to expand the global oligonucleotide API market size during the forecast period.
- Growth in Percentage of API Manufacturing Facilities - According to the US Food & Drug Administration (FDA), there were more than 28% of API manufacturing facilities based in the United States in 2019 catering to the market in the U.S. Rest of were located in other regions, including 13% in China.
- An Upsurge in Medical Approval Programs for Oligonucleotides - It was observed that as of 2019, around 605 oligonucleotide approval programs were in development throughout the world, compared with only 200 in 2010.
- Growing Expenditures on Healthcare Throughout the World - Global healthcare expenditure accounted for 9.83 billion in 2019 according to data provided by the World Bank, an increase from 9.7 billion in 2018.
- Rising per Capita Income Worldwide - The World Bank reported that worldwide annual per capita income increased by 4.8% in 2021, up from 1.5% in 2019.
Challenges
- High Production of Waste Associated with Oligonucleotide - The current state of the art in oligonucleotide synthesis provides a waste and expense burden to firms, with just 12 oligonucleotide pharmaceuticals having reached the market to date and hundreds more being developed in medical studies and preclinical research. So, the waste from the reversed-phase purification process comprises the hazardous waste disposal. For instance, solvent recovery is economically and environmentally advantageous at high production volumes, but around 50% of the waste volume still needs to be disposed of as aqueous-rich hazardous waste.
- Complex Procedure of Manufacturing
- Mandatory GMP Guidelines and Product Licensing
Oligonucleotide API Market Size and Forecast:
| Report Attribute | Details |
|---|---|
|
Base Year |
2025 |
|
Forecast Year |
2026-2035 |
|
CAGR |
9.7% |
|
Base Year Market Size (2025) |
USD 3.07 billion |
|
Forecast Year Market Size (2035) |
USD 7.75 billion |
|
Regional Scope |
|
Oligonucleotide API Market Segmentation:
End-user (Pharmaceutical Companies, Biotechnology Companies)
The global oligonucleotide API market is segmented and analyzed for demand and supply by end-user into pharmaceutical companies and biotechnology companies. Among these two segments, the pharmaceutical companies segment is estimated to gain the largest market share over the projected time frame. The growth of the segment can be attributed to the increasing adoption of innovative technology by pharmaceutical giants for improving drug efficacy and reducing development costs. For instance, a variety of oligonucleotides has become increasingly popular in the pharmaceutical industry, including antisense oligonucleotides, short-interfering RNAs, splice-switching oligonucleotides, microRNAs, immunostimulatory oligonucleotides, aptamers. The capacity to target the illness gene or the messenger RNAs (mRNAs) that are encoded by it has created new therapeutic possibilities. The length of therapeutic antisense oligonucleotides (ASOs) varies from 18 to 30 base pairs (bp).
API type {Short Interfering RNA (siRNA), Antisense Oligonucleotides, Phosphorodiamidate Morpholino Oligonucleotides (PMO), Aptamers, CpG Oligonucleotides, MiRNA API}
The global oligonucleotide API market is also segmented and analyzed for demand and supply by type into short interfering RNA (siRNA), antisense oligonucleotides, phosphorodiamidate morpholino oligonucleotides (PMO), aptamers, CpG oligonucleotides, MiRNA API, and others. Amongst these segments, the antisense oligonucleotides segment is expected to garner a significant share. The growth of the segment can be attributed to the rising focus on personalized medicine across the globe, along with the high efficiency of antisense for delivering effective results in the treatment. Besides this, antisense oligonucleotides deliver effective outcomes in Alzheimer’s treatment. Thus, spiking cases of Alzheimer’s is another factor that is projected to boost the growth of the segment in coming years. This, as a result, is anticipated to create numerous opportunities for the growth of the segment in the coming years.
Our in-depth analysis of the global market includes the following segments:
|
By API Type |
|
|
By Marketing Status |
|
|
By End User |
|
Vishnu Nair
Head - Global Business DevelopmentCustomize this report to your requirements — connect with our consultant for personalized insights and options.
Oligonucleotide API Market - Regional Analysis
North American Market Forecast
North America industry is estimated to hold largest revenue share of 36% by 2035, attributed majorly to increased healthcare spending, along with enhanced healthcare facilities in the region. The growth of the market can be attributed majorly to the increased healthcare spending, along with the enhanced healthcare facilities anticipated to fuel the oligonucleotide API market in the region over the forecast period. A recent report from the Centers for Medicare & Medicaid Services revealed that approximately 19.7% of GDP in the United States was spent on healthcare services in 2020, amounting to USD 4.1 trillion in total. In addition to this, surging R&D investments in novel drug discovery and commercialization of oligonucleotide therapies are also expected to further drive the regional market during the forecast period.
Europe Market Forecast
Furthermore, the European oligonucleotide API market is also estimated to display lucrative market growth by the end of 2035. The growth of the market can be attributed to the escalating investment in research and development activities in the region, followed by the presence of major players in the region. For instance, the biopharma sector in Europe region raised around USD 21 billion investment in 2018, and this amount surged by nearly 26% to USD 28 billion in 2019. Moreover, the rising focus on the development of precision medicine for cancer is another significant factor that is projected to boost the market growth further throughout the forecast period in the region.
Oligonucleotide API Market Players:
- Ionis Pharmaceuticals, Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Jazz Pharmaceuticals plc
- BIOGEN INC.
- Sarepta Therapeutics, Inc.
- Alnylam Pharmaceuticals, Inc.
- Corden Pharma International GmbH
- Nitto Denko Avecia, Inc.
- Merck KGaA
- Ajinomoto Co., Inc.
- Kaneka Eurogentec S.A.
Recent Developments
-
Ionis Pharmaceuticals, Inc. in collaboration with Biogen Inc., has announced the results of the investigation of the use of antisense oligonucleotide (ASO) for people with C9orf72-associated amyotrophic lateral sclerosis (ALS).
-
Jazz Pharmaceuticals plc has announced that its Zepzelca (Lurbinectedin) has been approved by the U.S. Food and Drug Administration(FDA), for treating adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.
- Report ID: 4308
- Published Date: Feb 25, 2026
- Report Format: PDF, PPT
- Explore a preview of key market trends and insights
- Review sample data tables and segment breakdowns
- Experience the quality of our visual data representations
- Evaluate our report structure and research methodology
- Get a glimpse of competitive landscape analysis
- Understand how regional forecasts are presented
- Assess the depth of company profiling and benchmarking
- Preview how actionable insights can support your strategy
Explore real data and analysis
Frequently Asked Questions (FAQ)
Oligonucleotide API Market Report Scope
Free Sample includes current and historical market size, growth trends, regional charts & tables, company profiles, segment-wise forecasts, and more.
Connect with our Expert
Copyright @ 2026 Research Nester. All Rights Reserved.
